Rational Problems Associated with the Development of Cellular Approaches in Controlling HIV Spread

Bourinbaiar, Aldar S.; Lee‐Huang, Sylvia

doi:10.1007/978-1-4615-1995-9_7

Cited by 8 publications

(7 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact the concept of alloimmunization for HIV indication has been promoted by many research groups for more than a decade but it has never received due consideration [39][40][41][42][43]. It is hoped that the new experimental evidence that became available recently will change this situation.…”

Section: Monkey Wrench: Alloimmunization As a Strategy For Aids Prevementioning

confidence: 96%

AIDS Vaccines and Reproductive Immunology

Bourinbaiar¹,

Jirathitikal²,

Silin³

et al. 2007

CIR

View full text Add to dashboard Cite

It may appear that problems of reproductive immunology have little in common with issues of treatment and prevention of AIDS. However, the certain aspects of HIV immunopathogenesis are closely related to problems faced by reproductive immunologists. The development of prophylactic and therapeutic AIDS vaccines would greatly benefit from acquired experience in immune regulation of reproductive dysfunction. The spermatozoa and HIV are foreign intruders that must enter the host cell, oocyte or T-lymphocyte, in order to start the replication process. The immune responses of the host organism against fertilized egg or HIV-impregnated lymphocyte must be similar, since in theory they are directed against alloantigens presented by such cells. This paper attempts to bring together the recent advances in AIDS field with progress made in the physiology and pathology of reproduction in humans, especially in the domain of immunotherapy and prevention of recurrent spontaneous abortions (RSA). It is our opinion that the lessons learned from alloimmunization trials of infertile women are relevant to prophylactic and therapeutic strategies for HIV infection.

show abstract

Section: Monkey Wrench: Alloimmunization As a Strategy For Aids Prevementioning

confidence: 96%

AIDS Vaccines and Reproductive Immunology

Bourinbaiar¹,

Jirathitikal²,

Silin³

et al. 2007

CIR

View full text Add to dashboard Cite

show abstract

“…These studies suggest that we have to remain open-minded in regard to the domineering hypothesis that vaccine primed T cell activation and the ensuing immune attack will always be beneficial to the host. Pros and cons for eliciting cell-mediated immunity against HIV were reviewed by us a few years ago, and the conclusions drawn in this review remain valid even today (21). Basically, it is possible that the CTL response induced by a vaccine may be protective to the vaccinee; however, the answer is by no means simple and straightforward.…”

Section: Ctl-mediated Immunitymentioning

confidence: 96%

“…The problem of oral tolerance is further complicated by peculiarities of the immunopathogenesis of HIV. We have previously reviewed the paradoxical nature of immune responses to HIV and the resulting clinical picture which does not fully agree with the textbook picture of classical pathogen-host interaction (21). It appears that in order to control HIV one does not need necessarily to activate the immune system and that a selective suppression of immune response may be a better strategy for HIV control.…”

Section: Oral Tolerancementioning

confidence: 96%

“…We don't know the nature of HIV inhibition by immune cells like CTL and what is the elusive CTL-secreted soluble factor that was first reported by Walker et al (158). Some of the available data suggests that CTL activation induced by a vaccine may enhance HIV replication and infectivity (14,15,21,61,131,144). We also don't know if a vaccine targeting both arms of immunity will work.…”

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

Mucosal AIDS Vaccines

Bourinbaiar¹,

Metadilogkul

Jirathitikal³

2003

Viral Immunology

Self Cite

View full text Add to dashboard Cite

Debates are still being waged over what is the best strategy for developing a potent AIDS vaccine. All the obvious approaches to making AIDS vaccines have been tried in the past two decades without much success. It is clear that new thinking and a revision of prevailing dogmas needs to be in place if we really want a vaccine. Conventional envelope-based antibody-inducing vaccines do not appear to hold promise, and broadly-neutralizing antibodies are now being searched as an alternative to the failed approach with subunit vaccines. The current consensus is that cellular immune responses, especially those mediated by CD8 cytotoxic/suppressor (CTL) and CD4 helper T lymphocytes, are needed to control HIV. Vaccines capable of inducing cell-mediated responses are, therefore, considered critical for controlling the spread of HIV. DNA-based vaccines triggering CTL reaction are currently thought to be an answer, but will they fulfill the promise? In the following paragraphs, a critical assessment of the state of the art will be provided in an attempt to analyze what we know and still don't know. The focus of this review is primarily on mucosal vaccines-a relatively new area in AIDS research. The update on V-1 Immunitor, the first mucosal AIDS vaccine available commercially, is provided within this context. Some of the reviewed concepts may be disputable, but without departure from the uninspiring consensus no substantial progress in the AIDS vaccine field can be envisioned.

show abstract

“…In the past we have investigated several drugs affecting primarily cellular functions [1] and found that they were acting as HIV inhibitors at pharmacologically relevant concentrations without exhibiting the cytotoxicity usually associated with administration of anti-HIV drugs like AZT. These compounds, e.g.…”

Section: Introductionmentioning

confidence: 99%

The non‐steroidal anti‐inflammatory drug, indomethacin, as an inhibitor of HIV replication

Bourinbaiar

Lee‐Huang

1995

FEBS Letters

Self Cite

View full text Add to dashboard Cite

Indomethacin, a common non-steroidal anti-inflammatory drug (NSAID), has been used to treat rheumatoid arthritis. Although indomethacin has also been used as an immunopotentiator and symptomatic NSAID in AIDS, its effect on HIV replication is unknown. MT-4 lymphocytes were inoculated with HIV in the presence of indomethacin and tested for p24 expression by ELISA. The 50% inhibition (IC5o) was 10 ~M, corresponding to plasma levels after administration of 50 mg oral indomethacin. The antiviral effect appears to be specific since no toxicity has been observed at the ICs0 dose, and unrelated NSAIDs have not shown the activity at clinical doses. Indomethacin may, thus, represent a new class of anti-HIV drug.

show abstract

Rational Problems Associated with the Development of Cellular Approaches in Controlling HIV Spread

Cited by 8 publications

References 123 publications

AIDS Vaccines and Reproductive Immunology

AIDS Vaccines and Reproductive Immunology

Mucosal AIDS Vaccines

The non‐steroidal anti‐inflammatory drug, indomethacin, as an inhibitor of HIV replication

Contact Info

Product

Resources

About